Mr. Robert Abenante reports

ABATTIS COMPLETES SALE OF NORTHERN VINE INTEREST

Abattis Bioceuticals Corp. has completed the sale of its 35-per-cent interest in Northern Vine Canada Inc. to Emerald Health Therapeutics Inc. in exchange for $2-million in cash and $4-million in common shares of Emerald Health Therapeutics, 50 per cent of which are free-trading shares and 50 per cent of which may be sold in 30 days.

"The sale of Northern Vine is a great achievement for Abattis," stated Rob Abenante, president and chief executive officer of Abattis Bioceuticals. "We learned several valuable lessons setting up this pilot lab, which will prove to be of tremendous value as we launch our second industrial-scale lab in Ontario with Xlabs."

The share purchase agreement governing the disposition also provides that, upon Northern Vine and/or Emerald Health Therapeutics earning gross revenues of $10-million from the sale of products or provision of services to customers introduced by Abattis Bioceuticals, Emerald Health Therapeutics will issue Abattis Bioceuticals an additional $4-million in common shares of Emerald Health Therapeutics.

In connection with the disposition, Abattis Bioceuticals has entered into a service and access agreement with Northern Vine to provide Abattis Bioceuticals' with continued use of Northern Vine's laboratory as a preferred customer, including with respect to Abattis Bioceuticals' development work on a hemp-infused, cannabinoid-rich, THC-free (tetrahydrocannabinol) craft beer with Faculty Brewing Co., and on nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil with the University of British Columbia (UBC).

"This disposition was very strategic for Abattis," added Mr. Abenante. "We have monetized our minority interest in Northern Vine and strengthened our financial position, while continuing to ramp up our focus on bringing revenue-generating products and services to the market. In addition, thanks to the services agreement, we are able to continue using the Northern Vine lab for our downstream service offerings on a preferred basis, including for our CBD [cannabidiol] beer and UBC research and development work.

"It has been a pleasure partnering with Emerald on Northern Vine and we look forward collaborating with them in the future on other projects."

About Abattis Bioceuticals Corp.

Abattis Bioceuticals is a leading diversified cannabis company, with interests in operations engaged in growing, extraction, testing, propagation and retail distribution. Through its partnership with Northern Vine Labs and its investment in XLABS Therapeutics (ONT) Inc., Abattis Bioceuticals has access to a fully licensed laboratory facility and an industrial-sized laboratory currently in the process of obtaining a Health Canada dealer's licence, and, through its wholly owned subsidiary Gabriola Green Farms, it has applied for a Health Canada licence to produce and sell cannabis flower and oils. Abattis Bioceuticals also operates a retail vaporizers business through its wholly owned subsidiary, Green Tree Therapeutics, which offers 10 unique branded SKUs on-line and across the country and owns a series of marketing, licensing and technology rights.

We seek Safe Harbor.